Mustang Bio, INC S-1 registration statements

Mustang Bio files for a potential offering of common stock, warrants, and pre-funded warrants to advance its CAR T therapy programs.

Mustang Bio plans a public offering of common stock and warrants to fund its CAR T therapy development for hematologic malignancies and solid tumors.

Mustang Bio is registering the resale of up to 6,497,800 shares of its common stock issuable upon the exercise of warrants held by selling stockholders.

Mustang Bio is registering the resale of up to 2,743,530 shares of common stock by selling stockholders upon exercise of warrants.

Mustang Bio is offering up to 15,625,000 shares of common stock and accompanying warrants in a public offering to raise capital for working capital, pipeline development, and general corporate purposes.

Mustang Bio is seeking to raise up to $5 million through a public offering of common stock and warrants to fund working capital and pipeline development.

Mustang Bio files an amendment to its S-1 registration statement to include exhibits related to securities purchase agreements and warrants.

Mustang Bio announces a proposed offering of common stock and warrants, or pre-funded warrants and warrants, aiming to raise capital for pipeline development and general corporate purposes.